



EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES
COMMONWEALTH OF MASSACHUSETTS
OFFICE OF MEDICAID
ONE ASHBURTON PLACE, BOSTON, MA 02108



MAURA T. HEALEY
GOVERNOR

KIAME MAHANIAH, MD, MBA
SECRETARY

KIMBERLEY DRISCOLL
LIEUTENANT GOVERNOR

RYAN SCHWARZ, MD, MBA
ASSISTANT SECRETARY
FOR MASSHEALTH

August 28, 2026

Chair Michael J. Rodrigues
Senate Committee on Ways and Means
State House, Room 212
Boston, MA 02133

Chair Aaron Michlewitz
House Committee on Ways and Means
State House, Room 243
Boston, MA 02133

Chair Cindy F. Friedman
Joint Committee on Health Care Financing
State House, Room 313
Boston, MA 02133

Chair John Lawn, Jr.
Joint Committee on Health Care Financing
State House, Room 236
Boston, MA 02133

Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn:

Chapter 9 of the Acts of 2025 line item 4000-0300 requires the Executive Office of Health and Human Services to submit a quarterly report including the projected total costs for the next fiscal year of pharmaceutical pipeline drugs identified by the executive office and expected to be made available for utilization within a 12-month period.

The Executive Office of Health and Human Services has identified 85 pipeline market entries from 94 manufacturers expected to be made available for utilization between April 1st, 2026, and March 31st, 2027. The estimated spend on the expected utilization of these products for all MassHealth members (including those enrolled with managed care) is approximately \$20M for the same time period. The prior quarterly report estimated a spend of \$20M based on the addition of 71 pipeline market entries from 76 manufacturers. High-cost cell and gene therapies remain the top drivers in spend.

Please contact Sarah Nordberg-Dunlea at Sarah.Nordberg@mass.gov if you have any questions about this report.

Sincerely,

Ryan Schwarz, MD, MBA
cc: Kiame Mahaniah, MD, MBA